Brevibloc

Brevibloc is a brand name of esmolol, approved by the FDA in the following formulation(s):

BREVIBLOC (esmolol hydrochloride - injectable; injection)

• 
  Manufacturer: BAXTER HLTHCARE CORP
  
  Approval date: February 25, 2003
  
  Strength(s): 10MG/ML ^[RLD][AP]

Has a generic version of Brevibloc been approved?

A generic version of Brevibloc has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Brevibloc and have been approved by the FDA:

esmolol hydrochloride injectable; injection

• 
  Manufacturer: APP PHARMS
  
  Approval date: May 2, 2005
  
  Strength(s): 10MG/ML ^[AP]


• 
  Manufacturer: BEDFORD LABS
  
  Approval date: August 10, 2004
  
  Strength(s): 10MG/ML ^[AP]


• 
  Manufacturer: BIONICHE PHARMA
  
  Approval date: May 2, 2005
  
  Strength(s): 10MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brevibloc. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Ready-to-use esmolol solution
  Patent 6,310,094
  Issued: October 30, 2001
  Inventor(s): Liu; Jie & Pejaver; Satish K. & Owoo; George
  Assignee(s): Baxter International Inc.
  A ready-to-use injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy] phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture in a container, is disclosed.
  
  Patent expiration dates:
  
  
  • January 12, 2021
    
  
  
  
  • July 12, 2021
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Esmolol formulation
  Patent 6,528,540
  Issued: March 4, 2003
  Inventor(s): Jie; Liu & Satish K.; Pejaver & George; Owoo
  Assignee(s): Baxter International Inc.
  An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture, are disclosed.
  
  Patent expiration dates:
  
  
  • January 12, 2021
    
  
  
  
  • July 12, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Brevibloc Consumer Information (Wolters Kluwer)
• Brevibloc Consumer Information (Cerner Multum)
• Brevibloc Advanced Consumer Information (Micromedex)
• Brevibloc AHFS DI Monographs (ASHP)
• Esmolol Consumer Information (Wolters Kluwer)
• Esmolol Consumer Information (Cerner Multum)
• Esmolol HCl Advanced Consumer Information (Micromedex)
• Esmolol Intravenous Advanced Consumer Information (Micromedex)
• Esmolol Hydrochloride AHFS DI Monographs (ASHP)